|
US4411993A
(en)
|
1981-04-29 |
1983-10-25 |
Steven Gillis |
Hybridoma antibody which inhibits interleukin 2 activity
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
US7008624B1
(en)
|
1995-02-22 |
2006-03-07 |
Immunex Corporation |
Antagonists of interleukin-15
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
PT1037927E
(pt)
|
1997-12-08 |
2004-10-29 |
Emd Lexigen Res Ct Corp |
Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
|
CN102766210B
(zh)
|
1999-08-24 |
2015-07-08 |
E.R.施贵宝&圣斯有限责任公司 |
人ctla-4抗体及其应用
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
EP1261376A1
(en)
|
2000-01-27 |
2002-12-04 |
Genetics Institute, LLC |
Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
|
|
DE10045592A1
(de)
*
|
2000-09-15 |
2002-03-28 |
Klaus Pfizenmaier |
Ein Antikörper-TNF-TNF Inhibitor Fusionsprotein (TNF-Selektokin) als zielspezifisches Prozytokin zur Tumortherapie
|
|
GB0100551D0
(en)
|
2001-01-09 |
2001-02-21 |
Queen Mary & Westfield College |
Protein
|
|
WO2003015697A2
(en)
|
2001-08-13 |
2003-02-27 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
IL160358A0
(en)
|
2001-08-23 |
2004-07-25 |
Genmab As |
Human antibodies specific for interleukin 15 (il-15)
|
|
NZ567242A
(en)
*
|
2001-10-04 |
2009-11-27 |
Genetics Inst Llc |
Use of an IL-21/IL-21R agonist for modulating interleukin-21 receptor activity and treating cancer
|
|
ES2629395T3
(es)
*
|
2001-10-04 |
2017-08-09 |
Genetics Institute, Llc |
Métodos y composiciones para modular la actividad de la interleucina-21
|
|
US8809504B2
(en)
|
2002-09-03 |
2014-08-19 |
Vit Lauermann |
Inhibitor which is deactivatable by a reagent produced by a target cell
|
|
US20060236411A1
(en)
|
2002-10-14 |
2006-10-19 |
Ingeborg Dreher |
Antagonists il-15
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
CN1921879A
(zh)
|
2003-12-29 |
2007-02-28 |
明斯特大学临床医学院 |
由il－15刺激和活化毛发生长的方法
|
|
AU2005203962C1
(en)
|
2004-01-05 |
2012-11-08 |
Antisoma Research Limited |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
ES2367027T3
(es)
|
2004-02-27 |
2011-10-27 |
Inserm (Institut National De La Santé Et De La Recherche Medicale) |
Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
|
|
CN1930300A
(zh)
|
2004-03-05 |
2007-03-14 |
希龙公司 |
预测患者治疗药物耐受性的体外试验系统
|
|
EP1723251A4
(en)
|
2004-03-05 |
2008-04-23 |
Novartis Vaccines & Diagnostic |
IN VITRO TEST SYSTEM FOR THE FORECASTING THE COMPATIBILITY OF A PATIENT AGAINST THERAPEUTICS
|
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
WO2008003473A2
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gmbh |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
|
WO2008074863A1
(en)
|
2006-12-21 |
2008-06-26 |
Novo Nordisk A/S |
Interleukin-21 variants with altered binding to the il-21 receptor
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
US8906356B2
(en)
|
2007-11-05 |
2014-12-09 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (IL-2) polypeptides
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
KR20160116056A
(ko)
|
2008-08-14 |
2016-10-06 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
항-ｉｌ-12/ｉｌ-23 항체
|
|
EP3281955A1
(en)
|
2008-10-02 |
2018-02-14 |
Aptevo Research and Development LLC |
Cd86 antagonist multi-target binding proteins
|
|
US20110274650A1
(en)
|
2009-01-21 |
2011-11-10 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
JP5587975B2
(ja)
|
2009-04-07 |
2014-09-10 |
ロシュ グリクアート アクチェンゲゼルシャフト |
二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体
|
|
EP2553101A4
(en)
*
|
2010-04-02 |
2013-09-04 |
Univ Rochester |
PROTEASE-ACTIVATED CYTOKINES
|
|
US9028830B2
(en)
|
2010-04-08 |
2015-05-12 |
JN Biosciences, LLC |
Antibodies to CD122
|
|
WO2012061536A2
(en)
|
2010-11-02 |
2012-05-10 |
The Trustees Of Columbia University In The City Of New York |
Methods for treating hair loss disorders
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
KR102591732B1
(ko)
|
2010-11-12 |
2023-10-19 |
넥타르 테라퓨틱스 |
Ｉｌ-2 부분 및 중합체의 접합체
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
ES2778053T3
(es)
|
2011-01-18 |
2020-08-07 |
Bioniz Llc |
Composiciones para modular la actividad de la citocina gamma-c
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
ES2657856T3
(es)
|
2011-03-02 |
2018-03-07 |
Roche Glycart Ag |
Anticuerpos CEA
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
GB201203442D0
(en)
|
2012-02-28 |
2012-04-11 |
Univ Birmingham |
Immunotherapeutic molecules and uses
|
|
BR112015002085A2
(pt)
|
2012-08-08 |
2017-12-19 |
Roche Glycart Ag |
proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
|
|
WO2014066527A2
(en)
|
2012-10-24 |
2014-05-01 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
JP6499087B2
(ja)
*
|
2013-02-26 |
2019-04-10 |
ロシュ グリクアート アーゲー |
二重特異性ｔ細胞活性化抗原結合分子
|
|
JP6815196B2
(ja)
|
2013-03-13 |
2021-01-20 |
イマジナブ、 インコーポレイテッド |
Ｃｄ８に対する抗原結合性構築物
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
WO2014146672A1
(en)
|
2013-03-18 |
2014-09-25 |
Ganymed Pharmaceuticals Ag |
Therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
AU2014377106B2
(en)
|
2014-01-08 |
2019-10-03 |
Jiangsu Hengrui Medicine Co., Ltd. |
IL-15 heterodimeric protein and uses thereof
|
|
WO2015110930A1
(en)
*
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
|
AR099625A1
(es)
|
2014-03-21 |
2016-08-03 |
Lilly Co Eli |
Anticuerpos de il-21
|
|
SI3128997T1
(sl)
|
2014-04-08 |
2020-11-30 |
Boston Pharmaceuticals Inc. |
Vezavne molekule specifične za IL-21 in njihove uporabe
|
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
|
WO2016014428A2
(en)
|
2014-07-21 |
2016-01-28 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
WO2016023040A1
(en)
|
2014-08-08 |
2016-02-11 |
Alexo Therapeutics International |
Sirp-alpha variant constructs and uses thereof
|
|
SI3482766T1
(sl)
|
2014-08-11 |
2020-09-30 |
Delinia, Inc. |
Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
|
|
CN104403004B
(zh)
|
2014-11-24 |
2017-10-13 |
苏州丁孚靶点生物技术有限公司 |
抗体‑干扰素异二聚体的制备和用途
|
|
WO2016086186A2
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies including binding to cd8
|
|
CA2969590A1
(en)
|
2014-12-03 |
2016-06-09 |
Rxi Pharmaceuticals Corporation |
Methods for the treatment of alopecia areata utilizing gene modulation approaches
|
|
LT3235830T
(lt)
*
|
2014-12-19 |
2020-12-28 |
Jiangsu Hengrui Medicine Co., Ltd. |
Interleukino 15 baltymų kompleksas ir jo naudojimas
|
|
JO3575B1
(ar)
|
2015-01-09 |
2020-07-05 |
Lilly Co Eli |
مركبات مساعد مشترك من gip وglp-1
|
|
EP3733696A1
(en)
*
|
2015-01-13 |
2020-11-04 |
City of Hope |
Ctla4-binding protein peptide-linker masks
|
|
WO2016112497A1
(zh)
|
2015-01-13 |
2016-07-21 |
中国人民解放军军事医学科学院生物工程研究所 |
人源抗人α干扰素抗体及其应用
|
|
US20160362469A1
(en)
|
2015-06-12 |
2016-12-15 |
Tianxin Wang |
Methods for protein modification in pharmaceutical applications
|
|
CN112574316A
(zh)
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
GB201513033D0
(en)
*
|
2015-07-23 |
2015-09-09 |
Ucb Biopharma Sprl |
Proteins
|
|
JP6800219B2
(ja)
|
2015-09-16 |
2020-12-16 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
特異的なインターロイキン−１５（ｉｌ−１５）アンタゴニストポリペプチド並びに炎症疾患及び自己免疫疾患の処置のためのその使用
|
|
SG11201804038VA
(en)
|
2016-01-08 |
2018-06-28 |
Univ California |
Conditionally active heterodimeric polypeptides and methods of use thereof
|
|
US20170204154A1
(en)
*
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
MA43724B1
(fr)
|
2016-03-22 |
2023-06-28 |
Hoffmann La Roche |
Molécules bispécifiques de cellules t activées par une protéase
|
|
US11326182B2
(en)
*
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
WO2018004338A1
(en)
|
2016-06-27 |
2018-01-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
|
BR112019007281A2
(pt)
|
2016-10-14 |
2019-07-09 |
Xencor Inc |
proteína heterodimérica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica e para tratar câncer em um paciente
|
|
TW202235438A
(zh)
*
|
2016-11-28 |
2022-09-16 |
日商中外製藥股份有限公司 |
能夠調節配體結合活性的配體結合分子
|
|
RS66900B1
(sr)
|
2016-12-21 |
2025-07-31 |
Cephalon Llc |
Antitela koja se specifično vezuju za humani il-15 i njihova upotreba
|
|
CN107082812B
(zh)
*
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
WO2018191438A1
(en)
|
2017-04-11 |
2018-10-18 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
EP3641829A4
(en)
|
2017-06-20 |
2021-04-21 |
The Board of Regents of The University of Texas System |
INTERFERON PRODRUG FOR TREATMENT OF CANCER
|
|
TWI901940B
(zh)
*
|
2017-08-03 |
2025-10-21 |
美商安進公司 |
介白素-21突變蛋白及治療方法
|
|
TWI831759B
(zh)
*
|
2017-12-01 |
2024-02-11 |
美商思進公司 |
Cd47抗體及其用於治療癌症之用途
|
|
WO2019129053A1
(zh)
|
2017-12-26 |
2019-07-04 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
BR112020014591A2
(pt)
|
2018-03-14 |
2020-12-01 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
anticorpos anticlaudina 18.2
|
|
CN110396133B
(zh)
|
2018-04-25 |
2021-07-23 |
免疫靶向有限公司 |
一种以白介素12为活性成分的融合蛋白型药物前体
|
|
WO2019222294A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
WO2019246392A1
(en)
|
2018-06-22 |
2019-12-26 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
TWI705820B
(zh)
|
2018-06-22 |
2020-10-01 |
美商美國禮來大藥廠 |
Gip/glp1促效劑組合物
|
|
MX2021003543A
(es)
|
2018-09-27 |
2021-06-23 |
Xilio Dev Inc |
Polipeptidos de citocinas enmascaradas.
|
|
CN110174363A
(zh)
|
2019-01-09 |
2019-08-27 |
北京九强生物技术股份有限公司 |
6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途
|
|
AU2020258384B2
(en)
|
2019-04-15 |
2026-05-14 |
Qwixel Therapeutics Llc |
Fusion protein composition(s) comprising targeted masked type I interferons (IFNA and IFNB) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
JP2022530677A
(ja)
|
2019-05-03 |
2022-06-30 |
バイオニズ リミテッド ライアビリティー カンパニー |
脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節
|
|
JP2022533254A
(ja)
|
2019-05-24 |
2022-07-21 |
プロヴィヴァ セラピューティクス （ホン コン） リミテッド |
Ｉｌ－２組成物およびその使用方法
|
|
CA3142738A1
(en)
|
2019-06-05 |
2020-12-10 |
Asher Biotherapeutics, Inc. |
Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function
|
|
WO2020252264A1
(en)
|
2019-06-12 |
2020-12-17 |
AskGene Pharma, Inc. |
Novel il-15 prodrugs and methods of use thereof
|
|
AU2020329216A1
(en)
|
2019-08-12 |
2022-02-24 |
AskGene Pharma, Inc. |
IL-2 fusion proteins that preferentially bind ILl-2ralpha
|
|
WO2021035188A1
(en)
|
2019-08-21 |
2021-02-25 |
AskGene Pharma, Inc. |
Novel il-21 prodrugs and methods of use thereof
|
|
AU2020353235A1
(en)
|
2019-09-28 |
2022-03-31 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
JP7767290B2
(ja)
|
2020-01-11 |
2025-11-11 |
アスクジーン・ファーマ・インコーポレイテッド |
新規なマスクされたサイトカインおよびその使用方法
|
|
EP4105238A4
(en)
|
2020-02-10 |
2024-03-27 |
Shanghai Escugen Biotechnology Co., Ltd. |
ANTI-CLAUDINE ANTIBODIES 18.2 AND ASSOCIATED USE
|
|
JP7792395B2
(ja)
|
2020-08-06 |
2025-12-25 |
アブプロ コーポレーション |
抗クローディン１８．２多重特異性抗体及びそれらの使用
|
|
EP4277707A1
(en)
|
2021-01-14 |
2023-11-22 |
Askgene Pharma, Inc. |
Interferon prodrugs and methods of making and using the same
|
|
WO2022159395A1
(en)
|
2021-01-20 |
2022-07-28 |
Viking Therapeutics, Inc. |
Compositions and methods for the treatment of metabolic and liver disorders
|
|
US20240076331A1
(en)
|
2021-02-01 |
2024-03-07 |
AskGene Pharma, Inc. |
Chimeric Molecules Comprising an IL-10 or TGF-Beta Agonist Polypeptide
|
|
WO2022178103A1
(en)
|
2021-02-17 |
2022-08-25 |
AskGene Pharma, Inc. |
Il-2 receptor beta subunit mutants
|
|
EP4323392A4
(en)
|
2021-04-16 |
2025-03-19 |
Orionis Biosciences, Inc. |
IL-2-BASED CONSTRUCTS
|
|
IL311411A
(en)
|
2021-09-15 |
2024-05-01 |
Viking Therapeutics Inc |
Preparations and methods for the treatment of metabolic and liver disorders
|
|
WO2024119193A2
(en)
|
2022-12-02 |
2024-06-06 |
AskGene Pharma, Inc. |
Mutant il-2 polypeptides and il-2 prodrugs
|
|
CN118307678A
(zh)
|
2023-06-07 |
2024-07-09 |
北京义翘神州科技股份有限公司 |
一种抗cldn18_2的抗体
|